Kyndrisa Approval Status
- FDA approved: No
- Brand name: Kyndrisa
- Generic name: drisapersen
- Company: BioMarin Pharmaceutical Inc.
- Treatment for: Duchenne Muscular Dystrophy
Kyndrisa (drisapersen) is an investigational antisense oligonucleotide in development for the treatment of Duchenne muscular dystrophy amenable to exon 51 skipping.In January 2016, BioMarin Pharmaceutical Inc. announced the receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA) advising the company that the New Drug Application for Kyndrisa was not ready for approval in its present form. The FDA concluded that the standard of substantial evidence of effectiveness had not been met. BioMarin will review the Complete Response Letter and work with the FDA to determine the appropriate steps regarding future of the application.
Development Status and FDA Approval Process for Kyndrisa
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.